TIME-CHF ) Randomized Trial Elderly Patients With Congestive Heart Failure The Trial of Intensified vs Standard Medical Therapy in BNP-Guided vs Symptom-Guided Heart Failure Therapy :
暂无分享,去创建一个
M. Pfisterer | M. Schieber | P. Erne | P. Buser | T. Suter | H. Rickli | P. Dubach | P. Rickenbacher | H. Osterhues | M. Gutmann | A. Vuillomenet | Urs Jeker | H. Beer | Se-Il Yoon | P. Hilti
[1] J. Struck,et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2008, Journal of the American College of Cardiology.
[2] M. Cheitlin,et al. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .
[3] A. Jánosi,et al. Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.
[4] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[5] S. Normand,et al. National trends in outcomes among elderly patients with heart failure. , 2006, The American journal of medicine.
[6] M. Pfisterer,et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.
[7] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[8] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[9] A. Cohen-Solal,et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.
[10] John G.F. Cleland,et al. [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. , 2005, Revista espanola de cardiologia.
[11] B. Yawn,et al. Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.
[12] M. Pfisterer,et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.
[13] S. Willich,et al. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease , 2003, Heart.
[14] S. Gottlieb,et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. , 2004, European heart journal.
[15] H. Krum,et al. Demographics and concomitant disorders in heart failure , 2003, The Lancet.
[16] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[17] C. Frampton,et al. B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.
[18] B. Pitt,et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[19] N Freemantle,et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.
[20] Harlan M Krumholz,et al. Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.
[21] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[22] C. Frampton,et al. Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) levels improves outcome , 2000 .
[23] J. Pell,et al. Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.
[24] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[25] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[26] G. Lamas,et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.
[27] J. Cohn,et al. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. , 1993, The American journal of cardiology.
[28] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[29] M A Hlatky,et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). , 1989, The American journal of cardiology.